New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials

2012 ◽  
Vol 48 (8) ◽  
pp. 1176-1184 ◽  
Author(s):  
Thierry Gorlia ◽  
Roger Stupp ◽  
Alba A. Brandes ◽  
Roy R. Rampling ◽  
Pierre Fumoleau ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Prognostic Factors ◽  
Phase I ◽  
Brain Tumour ◽  
Outcome Prediction ◽  
Pooled Analysis ◽  
Recurrent Glioblastoma ◽  
Tumour Group ◽  
Phase I And Ii

scholarly journals Osteosarcoma Pathogenesis Leads the Way to New Target Treatments

2021 ◽  
Vol 22 (2) ◽  
pp. 813
Author(s):  
Isabel Fernandes ◽  
Cecília Melo-Alvim ◽  
Raquel Lopes-Brás ◽  
Miguel Esperança-Martins ◽  
Luís Costa
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Poor Prognosis ◽  
Therapeutic Targets ◽  
Rare Condition ◽  
Basic Research ◽  
Metastatic Setting ◽  
Phase I And Ii ◽  
The Way

Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets.

Toxicity profiles of HER2/neupeptide anticancer vaccines: the picture from Phase/I and II clinical trials

2012 ◽  
Vol 11 (6) ◽  
pp. 637-640 ◽  
Author(s):  
Constantin N Baxevanis ◽  
Michael Papamichail ◽  
Sonia A Perez
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Anticancer Vaccines ◽  
Phase I And Ii

Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD)

2020 ◽  
Vol 29 (7) ◽  
pp. 723-738
Author(s):  
Luigino Calzetta ◽  
Beatrice Ludovica Ritondo ◽  
Maria Gabriella Matera ◽  
Gabriella Pezzuto ◽  
Mario Cazzola ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Obstructive Pulmonary Disease ◽  
Clinical Trials ◽  
Phase I ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Phase I And Ii

Stereobody radiotherapy for nodal recurrences in oligometastatic patients: a pooled analysis from two phase I clinical trials

2020 ◽  
Vol 37 (4) ◽  
pp. 519-529
Author(s):  
Francesco Deodato ◽  
Milena Ferro ◽  
Savino Cilla ◽  
Anna Ianiro ◽  
Milly Buwenge ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Phase I ◽  
Pooled Analysis ◽  
Phase I Clinical Trials ◽  
Two Phase

Tolerability of pemetrexed and oxaliplatin in the treatment of stage III colon cancer during raltitrexed shortage

2020 ◽  
pp. 107815522093416
Author(s):  
Jasmine Giani ◽  
Michael B Sawyer ◽  
Carole Chambers
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Clinical Trials ◽  
Case Report ◽  
Adverse Events ◽  
Phase I ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Colorectal Cancer Treatment ◽  
Phase I And Ii

Colorectal cancer is one of the most common malignancies diagnosed in Canada. Currently, adjuvant colorectal cancer treatment primarily includes chemotherapeutic regimens such as FOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin) or CAPOX (capecitabine, oxaliplatin), as well as alternative regimens such as TOMOX (raltitrexed, oxaliplatin). However, the prevalence of drug shortages in today’s society may make these preferred regimens inaccessible. The purpose of this case report is to highlight the tolerability of an alternative adjuvant regimen (pemetrexed plus oxaliplatin) that has undergone both phase I and II clinical trials for the treatment of colorectal cancer. The patient presented in this case report is a 57-year-old female diagnosed with Stage III colon cancer. This patient received seven cycles of pemetrexed plus oxaliplatin and experienced several adverse events, with the majority of them being mild in nature including fatigue and cold dysesthesia. However, the patient also experienced progressive neuropathy which required a dose reduction and subsequent discontinuation of oxaliplatin. Overall, pemetrexed and oxaliplatin’s tolerability seems comparable to other regimens used to treat colorectal cancer and could potentially be an option to consider in the future for alternative treatment of colorectal cancer pending further trials.

Prognostic factors for cancer patients with good performance status considered for inclusion in phase I clinical trials

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 2568-2568
Author(s):  
M. Bonneterre ◽  
N. Penel ◽  
M. Vanseymortier ◽  
E. Dansin ◽  
S. Clisant ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Prognostic Factors ◽  
Serum Albumin ◽  
Phase I ◽  
Cancer Patients ◽  
Cox Model ◽  
Performance Status ◽  
Univariate Analysis ◽  
Rank Test ◽  
Phase I Clinical Trials

2568 Background: For investigators, the selection of patients to be considered for phase I clinical trials is difficult, because of the lack of objective criteria for a rational decision-making process. From October 1997 to October 2002, we retrospectively assessed prognostic factors for cancer patients considered for Phase 1 trials. Methods: 148 consecutive patients who had been screened for inclusion in 6 different phase I trials were included in the present study. 70 out of them actually received the phase I treatment. Univariate (Log-Rank test) and multivariate analysis (Cox proportional hazard ratio model) were performed to determine the prognostic factors related to overall survival (OS) after screening. Results: The study comprised 63 men and 85 women, with a median age of 54 (range 23–79). The most frequent primary cancer sites were: breast (38 cases), head and neck (28 cases), lung (18 cases) and colorectal (17 cases). 91 out of them had a performance status PS = 0. The median OS of the 148 patients was 5.7 months (173 days, range 1–2,421). Univariate analysis identified PS = 1, Body Mass Index < 20, liver and visceral metastasis, serum albumin < 38 g/L, lymphocytes count < 0.7 x 109/L and granulocytes count > 7.5 x 109/L as poor prognostic factors. The Cox model identified serum albumin < 38 g/L (HR 2.51 [1.51–4.18], p=0.0001) and lymphocyte count < 0.7 x 109/L (HR 2.27 [1.13–4.62], p=0.024) as independent prognostic variables for OS. All patients presenting with both prognostic factors died within 90 days. Conclusion: We propose a simple model, easily obtained at the patient bedside, which can discriminate patients who have a life expectancy of over 3 months and thus could be enrolled in phase-I anti-cancer trials. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document